HuR in Allergic Asthma and T cell Differentiation

HuR 在过敏性哮喘和 T 细胞分化中的作用

基本信息

  • 批准号:
    9590179
  • 负责人:
  • 金额:
    $ 17.7万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-08-14 至 2020-02-29
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): For unknown reasons, the incidence of allergies and asthma continues to increase in the US. It is increasingly clear that asthma is a heterogeneous disease with differing endotypes which suggest discrete pathophysiology. In humans, asthma exists in allergic and non-allergic forms. It is an unmet need in the field to better understand ho different mechanisms contribute to asthma endotypes. Genome wide array analysis has identified many asthma relevant genes. However, due to poor correlation between steady state mRNA levels and protein, transcriptomic approaches may overlook critical genes. Posttranscriptional gene regulation by RNA binding proteins (RBPs) and microRNAs (miRNAs) are increasingly recognized as important control mechanisms for proinflammatory genes. RBPs, such as HuR (elav1) which bind to AU-rich elements (AREs) play critical roles in coordinately regulating proinflammatory genes in asthma by stabilizing target gene mRNAs and increasing translatability. Methods used by our lab and others, called RNA immunoprecipitation applied to microarrays (RIP-Chip) have identified how RBPs are coordinately regulating inflammation. Posttranscriptional gene regulation plays an important role in CD4+ T differentiation, yet these processes are poorly understood. Our long term goal is to understand posttranscriptional gene regulation in airway inflammation. The objective of this application, which is our next step in pursuit of that goal, is to understand how HuR is regulating key molecules, such as Th2/Th17 cytokines and IL-2 during allergen challenge. The central esis is that the RBP, HuR, is permissive for development of CD4+ Th2 mediated allergic airway inflammation and required for normal IL-2 homeostatic expression. The rationale for this proposal is that our work has demonstrated that HuR controls both Th2 and Th17 differentiation. HuR KO mice do not develop airway inflammation due to suppression of Th2 cytokine production and do not have the ability to turn off IL-2 expression following T cell activation. Understanding posttranscriptional mechanisms of IL-2 and Th2/Th17 cytokine gene regulation will allow the field to modulate and affect outcomes of inflammatory responses in allergen driven asthma and also perhaps aid in better defining the heterogeneity amongst asthma endotypes. We plan to test the central esis and accomplish these objectives by the following four specific aims: 1) Does HuR ablation alter CD4+ Th subset differentiation?; 2) Determine whether HuR is required for allergic airway inflammation in vivo; 3) Mechanistic determinants of IL-2 and Th2 cytokine expression; 4) Determine whether human lymphocytes have dysregulated HuR expression. We believe our study is innovative, because such approaches will provide novel mechanistic insights into T cell posttranscriptional cytokine regulation. The proposed research is significant, because it will elucidate how airway responses connect at the molecular level with both adaptive and innate immunity to control lung inflammation.
描述(由申请人提供):由于未知的原因,美国过敏和哮喘的发病率持续增加。越来越清楚的是,哮喘是一种异质性疾病,具有不同的内型,这表明其病理生理学是离散的。在人类中,哮喘以过敏性和非过敏性形式存在。更好地了解不同机制如何导致哮喘内型是该领域未满足的需求。全基因组分析已鉴定出许多哮喘相关基因。然而,由于稳态 mRNA 水平和蛋白质之间的相关性较差,转录组学方法可能会忽略关键基因。 RNA 结合蛋白 (RBP) 和 microRNA (miRNA) 的转录后基因调控越来越被认为是促炎基因的重要控制机制。 RBP,例如与富含 AU 的元件 (ARE) 结合的 HuR (elav1),通过稳定靶基因 mRNA 和增加可翻译性,在协调调节哮喘促炎基因方面发挥着关键作用。我们的实验室和其他实验室使用的方法(称为应用于微阵列的 RNA 免疫沉淀法 (RIP-Chip))已经确定了 RBP 如何协调调节炎症。转录后基因调控在 CD4+ T 分化中发挥着重要作用,但人们对这些过程知之甚少。我们的长期目标是了解气道炎症中的转录后基因调控。该应用程序的目的是了解 HuR 在过敏原挑战过程中如何调节关键分子,例如 Th2/Th17 细胞因子和 IL-2,这是我们追求这一目标的下一步。核心观点是,RBP、HuR 允许 CD4+ Th2 介导的过敏性气道炎症的发生,并且是正常 IL-2 稳态表达所必需的。该提议的基本原理是我们的工作已经证明 HuR 控制 Th2 和 Th17 分化。 HuR KO 小鼠不会因 Th2 细胞因子产生的抑制而发生气道炎症,并且不具备在 T 细胞激活后关闭 IL-2 表达的能力。了解 IL-2 和 Th2/Th17 细胞因子基因调控的转录后机制将使该领域能够调节和影响过敏原驱动的哮喘中炎症反应的结果,并且可能有助于更好地定义哮喘内型之间的异质性。我们计划测试中心 esis 并通过以下四个具体目标来实现这些目标:1)HuR 消融是否会改变 CD4+ Th 子集分化? 2)确定体内过敏性气道炎症是否需要HuR; 3)IL-2和Th2细胞因子表达的机制决定因素; 4) 确定人淋巴细胞是否存在HuR表达失调。我们相信我们的研究具有创新性,因为此类方法将为 T 细胞转录后细胞因子调节提供新的机制见解。拟议的研究意义重大,因为它将阐明气道反应如何在分子水平上与适应性和先天免疫联系起来以控制肺部炎症。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ULUS ATASOY其他文献

ULUS ATASOY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ULUS ATASOY', 18)}}的其他基金

Mechanisms of HuR Overexpression in Asthmatic Endotypes
哮喘内型中 HuR 过度表达的机制
  • 批准号:
    10570322
  • 财政年份:
    2023
  • 资助金额:
    $ 17.7万
  • 项目类别:
Molecular mechanisms of posttranscriptional gene regulation in asthmatic airway inflammation
哮喘气道炎症转录后基因调控的分子机制
  • 批准号:
    10698606
  • 财政年份:
    2023
  • 资助金额:
    $ 17.7万
  • 项目类别:
HuR in Allergic Asthma
过敏性哮喘中的 HuR
  • 批准号:
    8090588
  • 财政年份:
    2010
  • 资助金额:
    $ 17.7万
  • 项目类别:
HuR in Allergic Asthma
过敏性哮喘中的 HuR
  • 批准号:
    8070070
  • 财政年份:
    2010
  • 资助金额:
    $ 17.7万
  • 项目类别:
HuR in Allergic Asthma
过敏性哮喘中的 HuR
  • 批准号:
    7729032
  • 财政年份:
    2009
  • 资助金额:
    $ 17.7万
  • 项目类别:
Posttranscriptional Gene Regulation in Asthma
哮喘的转录后基因调控
  • 批准号:
    7659902
  • 财政年份:
    2009
  • 资助金额:
    $ 17.7万
  • 项目类别:
HuR in Allergic Asthma and T Cell Differentiation
HuR 在过敏性哮喘和 T 细胞分化中的作用
  • 批准号:
    9225152
  • 财政年份:
    2009
  • 资助金额:
    $ 17.7万
  • 项目类别:
HuR in Allergic Asthma
过敏性哮喘中的 HuR
  • 批准号:
    8107658
  • 财政年份:
    2009
  • 资助金额:
    $ 17.7万
  • 项目类别:
Posttranscriptional Gene Regulation in Asthma
哮喘的转录后基因调控
  • 批准号:
    7847589
  • 财政年份:
    2009
  • 资助金额:
    $ 17.7万
  • 项目类别:
HuR in Allergic Asthma
过敏性哮喘中的 HuR
  • 批准号:
    8307413
  • 财政年份:
    2009
  • 资助金额:
    $ 17.7万
  • 项目类别:

相似海外基金

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
  • 批准号:
    10682121
  • 财政年份:
    2023
  • 资助金额:
    $ 17.7万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10576370
  • 财政年份:
    2022
  • 资助金额:
    $ 17.7万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10387023
  • 财政年份:
    2022
  • 资助金额:
    $ 17.7万
  • 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10248409
  • 财政年份:
    2019
  • 资助金额:
    $ 17.7万
  • 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
  • 批准号:
    nhmrc : GNT1163111
  • 财政年份:
    2019
  • 资助金额:
    $ 17.7万
  • 项目类别:
    Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10462684
  • 财政年份:
    2019
  • 资助金额:
    $ 17.7万
  • 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
  • 批准号:
    398018062
  • 财政年份:
    2018
  • 资助金额:
    $ 17.7万
  • 项目类别:
    Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9308643
  • 财政年份:
    2017
  • 资助金额:
    $ 17.7万
  • 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9447149
  • 财政年份:
    2017
  • 资助金额:
    $ 17.7万
  • 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
  • 批准号:
    8893915
  • 财政年份:
    2014
  • 资助金额:
    $ 17.7万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了